Abstract
This study investigates the long-term outcomes of clival chordoma patients treated with the endonasal transclival approach (ETCA) and early adjuvant radiation therapy. A retrospective review of 17 patients (2002–2013) showed a 10-year progression-free survival (PFS) rate of 67.4%, with the ETCA group showing fewer progressions and cranial neuropathies than those treated with combined approaches. The ETCA, a minimally invasive technique, provided a similar extent of resection compared to conventional skull-base approaches and enabled safe delivery of high-dose adjuvant radiotherapy. The findings suggest that ETCA is an effective treatment for centrally located clival chordomas.
Funding Information
  • 2022 AO Spine National Research Grant (AOSKRR202205, 2022R1C1C2008148)
  • National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (AOSKRR202205, 2022R1C1C2008148)

This publication has 39 references indexed in Scilit: